---
figid: PMC7698938__ijms-21-08712-g005
figtitle: Mechanisms of therapeutic effects of Cinacalcet on CKD-MBD
organisms:
- Homo sapiens
- Mus musculus
pmcid: PMC7698938
filename: ijms-21-08712-g005.jpg
figlink: pmc/articles/PMC7698938/figure/ijms-21-08712-f005/
number: F5
caption: Potential mechanisms of therapeutic effects of Cinacalcet on CKD-MBD. The
  schematic diagram illustrates that increased SOST expression in patients with secondary
  hyperparathyroidism inhibits Wnt 10b/Wnt 16 signaling pathway, leading to activating
  osteoclastic bone resorption (TRACP-5b) and inactivating osteoblastic bone formation
  (PINP), and ultimately bone inflammation and low bone density. Beyond iPTH suppression,
  Cinacalcet therapy intensifies bone density through inhibiting SOST expression and
  upregulating Wnt-10b/Wnt 16 signaling that activates osteoblastic bone formation
  (PINP) and inactivates osteoclastic bone resorption (TRACP-5b), along with the improvement
  of inflammatory milieu (CRP). CKD-MBD, chronic kidney disease and mineral bone disease;
  CRP, C-reactive protein; iPTH, intact parathyroid hormone; PINP, procollagen type
  I propeptides; SOST, sclerostin; TRACP-5b, tartrate-resistant acid phosphatase isoform
  5b; Wnt, Wingless and int-1; ↑, increase; ↓, decrease.
papertitle: Therapeutic Effect of Calcimimetics on Osteoclast–Osteoblast Crosslink
  in Chronic Kidney Disease and Mineral Bone Disease.
reftext: Kuo-Chin Hung, et al. Int J Mol Sci. 2020 Nov;21(22):8712.
year: '2020'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.8809514
figid_alias: PMC7698938__F5
figtype: Figure
organisms_ner:
- Homo sapiens
- Mus musculus
redirect_from: /figures/PMC7698938__F5
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC7698938__ijms-21-08712-g005.html
  '@type': Dataset
  description: Potential mechanisms of therapeutic effects of Cinacalcet on CKD-MBD.
    The schematic diagram illustrates that increased SOST expression in patients with
    secondary hyperparathyroidism inhibits Wnt 10b/Wnt 16 signaling pathway, leading
    to activating osteoclastic bone resorption (TRACP-5b) and inactivating osteoblastic
    bone formation (PINP), and ultimately bone inflammation and low bone density.
    Beyond iPTH suppression, Cinacalcet therapy intensifies bone density through inhibiting
    SOST expression and upregulating Wnt-10b/Wnt 16 signaling that activates osteoblastic
    bone formation (PINP) and inactivates osteoclastic bone resorption (TRACP-5b),
    along with the improvement of inflammatory milieu (CRP). CKD-MBD, chronic kidney
    disease and mineral bone disease; CRP, C-reactive protein; iPTH, intact parathyroid
    hormone; PINP, procollagen type I propeptides; SOST, sclerostin; TRACP-5b, tartrate-resistant
    acid phosphatase isoform 5b; Wnt, Wingless and int-1; ↑, increase; ↓, decrease.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - SOST
  - WNT1
  - WNT2
  - WNT2B
  - WNT3
  - WNT3A
  - WNT4
  - WNT6
  - WNT7A
  - WNT7B
  - WNT8A
  - WNT8B
  - WNT9A
  - WNT9B
  - WNT10A
  - WNT10B
  - WNT11
  - WNT16
  - WNT5A
  - WNT5B
  - ACP5
  - PTH
  - PTRH2
  - CRP
  - CSRP1
  - PPIAP10
  - Sost
  - Wnt10b
  - Foxm1
  - Pth
  - Ptrh1
  - Crp
  - Dmbt1
  - Crip2
---
